Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety

Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation.

S Sawada, Gen Suzuki, Yoshiko Kawase et al. · The Journal of Immunology · 1987 · 417 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Vernal keratoconjunctivitis revisited

Stefano Bonini, Alessandro Lambìase, S. Marchi et al. · Ophthalmology · 2000 · 413 citations

A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance

Stephen C. Pflugfelder, Steven L. Maskin, Bruce D. Anderson et al. · American Journal of Ophthalmology · 2004 · 231 citations

Pharmacy, Ophthalmology, Pharmacotherapy +9

Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis

Neri Pucci, Elio Novembre, Antonella Cianferoni et al. · Annals of Allergy Asthma & Immunology · 2002 · 170 citations

Medicine, Dermatology, Ophthalmology +10

Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis

Ahmad Kheirkhah, Mehdi Khodaparast Zavareh, Farzad Farzbod et al. · Eye · 2011 · 97 citations · Full text

Medicine, Dermatology, Ophthalmology +6